---
title: "Compass Therapeutics: Buy Rating Reiterated as Clinical Progress Strengthens Approval Odds; $6 Price Target Maintained"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285256239.md"
description: "Analyst Charles Zhu from LifeSci Capital has reiterated a Buy rating on Compass Therapeutics, maintaining a price target of $6.00. This decision is based on the company's clinical progress and regulatory outlook, particularly the COMPANION-002 results, which enhance approval odds. Upcoming catalysts and a solid cash runway further support this rating. H.C. Wainwright also reaffirmed a Buy rating with a higher price target of $24.00."
datetime: "2026-05-05T19:55:33.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285256239.md)
  - [en](https://longbridge.com/en/news/285256239.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285256239.md)
---

# Compass Therapeutics: Buy Rating Reiterated as Clinical Progress Strengthens Approval Odds; $6 Price Target Maintained

Analyst Charles Zhu from LifeSci Capital maintained a Buy rating on Compass Therapeutics and keeping the price target at $6.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Charles Zhu has given his Buy rating due to a combination of factors tied to Compass Therapeutics’ clinical progress and regulatory outlook. He views the COMPANION-002 results as materially strengthening the probability of approval, with management already preparing for a BLA filing and expecting clarity on the FDA path by around Labor Day, underpinned by a strongly positive progression-free survival signal despite a non-significant overall survival hazard ratio.

Zhu also highlights upcoming catalysts from the PD-1 x PD-L1 bispecific CTX-8371 and PD-1 x VEGF bispecific CTX-10726, including dose-escalation and early safety/efficacy readouts that could expand the company’s value proposition across multiple tumor types. Combined with a solid cash runway, ongoing Phase 2 planning for tovecimig, and active investigator-sponsored work in first-line biliary tract cancer, he sees a favorable risk-reward profile that supports maintaining a $6 price target and a Buy rating on CMPX shares.

In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $24.00 price target.

### Related Stocks

- [CMPX.US](https://longbridge.com/en/quote/CMPX.US.md)

## Related News & Research

- [Analyst Maintains Buy on Tovecimig Developer, Sees PFS Strength Underappreciated and Keeps $24 Price Target Unchanged](https://longbridge.com/en/news/284246322.md)
- [LifeSci Capital Sticks to Its Buy Rating for Compass Therapeutics (CMPX)](https://longbridge.com/en/news/284243897.md)
- [Goldman Sachs Sticks to Their Buy Rating for Autolus Therapeutics (AUTL)](https://longbridge.com/en/news/286522682.md)
- [Barclays Remains a Buy on Oruka Therapeutics (ORKA)](https://longbridge.com/en/news/286389801.md)
- [Bank of America Securities Reaffirms Their Buy Rating on Inhibikase Therapeutics (IKT)](https://longbridge.com/en/news/286542293.md)